BCTXL

Briacell Therapeutics Corp

• Reuters·03/31 20:07

  BriaPro buys BriaCell soluble CD80 cancer therapy license, BriaCell stake rises to 78%

• Reuters·03/18 11:30

  BriaCell to present four posters at the AACR Annual Meeting

• Reuters·03/17 14:32

  BriaCell reports 9 of 25 Phase 2 metastatic breast cancer patients alive more than 18-47 months post-enrollment

• Reuters·03/10 21:09

  BriaCell Therapeutics Q2 FY2026 net loss widens 15% to USD 7.3 million

• Reuters·03/10 11:53

  BriaCell to present four posters at the AACR Annual Meeting

• Reuters·02/20 21:01

  BriaPro to Buy BriaCell’s Exclusive Soluble CD80 License in Asset Deal

• Reuters·02/18 22:30

  BriaPro to Buy BriaCell’s Exclusive Soluble CD80 License in Asset Deal

• Reuters·02/18 22:30

  BRIACELL THERAPEUTICS CORP: AS PART OF TRANSACTION, BRIACELL WILL MAKE AVAILABLE TO BRIAPRO UP TO $3 MLN TO FUND RESEARCH AND DEVELOPMENT EFFORT

• Reuters·02/17 12:30

  BRIACELL RECEIVES POSITIVE RECOMMENDATION FROM DATA SAFETY MONITORING BOARD (DSMB) FOR PHASE 3 STUDY IN METASTATIC BREAST CANCER

• Reuters·02/17 12:30

  BriaCell Advances Phase 3 Bria-IMT Study After Positive Safety Review

• Reuters·02/12 21:01

  BriaCell Therapeutics Corp. Announces Date for Upcoming Annual General and Special Meeting of Shareholders

• Reuters·01/28 12:30

  BriaCell Therapeutics Reports Tumor Regression in Phase 2 Study of Bria-IMT for Metastatic Breast Cancer

• Reuters·01/28 12:30

  BRIACELL PATIENTS’ IMAGES SHOW REGRESSION AND RESOLUTION OF METASTASIZED TUMORS AND IMMUNE ACTIVATION

• Reuters·01/27 17:05

  BriaCell Reports Extended Survival in Phase 2 Metastatic Breast Cancer Trial

• Reuters·01/27 12:30

  BriaCell Highlights Extended >18-47 MONTHS SURVIVAL IN PHASE 2 METASTATIC BREAST CANCER PATIENTS